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Abstract
Objectives To derive and validate a new clinical risk prediction algorithm
(QThrombosis, www.qthrombosis.org) to estimate individual patients’
risk of venous thromboembolism.
Design Prospective open cohort study using routinely collected data
from general practices. Cox proportional hazards models used in
derivation cohort to derive risk equations evaluated at 1 and 5 years.
Measures of calibration and discrimination undertaken in validation
cohort.
Setting 564 general practices in England and Wales contributing to the
QResearch database.
Participants Patients aged 25-84 years, with no record of pregnancy
in the preceding 12 months or any previous venous thromboembolism,
and not prescribed oral anticoagulation at baseline: 2 314 701 in
derivation cohort and 1 240 602 in validation cohort.
Outcomes Incident cases of venous thromboembolism, either deep vein
thrombosis or pulmonary embolism, recorded in primary care records
or linked cause of death records.
Results The derivation cohort included 14 756 incident cases of venous
thromboembolism from 10 095 199 person years of observation (rate of
14.6 per 10 000 person years). The validation cohort included 6913
incident cases from 4 632 694 person years of observation (14.9 per 10
000 person years). Independent predictors included in the final model
for men and women were age, body mass index, smoking status,
varicose veins, congestive cardiac failure, chronic renal disease, cancer,
chronic obstructive pulmonary disease, inflammatory bowel disease,
hospital admission in past six months, and current prescriptions for
antipsychotic drugs. We also included oral contraceptives, tamoxifen,
and hormone replacement therapy in the final model for women. The
risk prediction equation explained 33% of the variation in women and
34% in men in the validation cohort evaluated at 5 years The D statistic
was 1.43 for women and 1.45 for men. The receiver operating curve
statistic was 0.75 for both sexes. The model was well calibrated.
Conclusions We have developed and validated a new risk prediction
model that quantifies absolute risk of thrombosis at 1 and 5 years. It can
help identify patients at high risk of venous thromboembolism for
prevention. The algorithm is based on simple clinical variables which
the patient is likely to know or which are routinely recorded in general
practice records. The algorithm could be integrated into general practice
clinical computer systems and used to risk assess patients before
hospital admission or starting medication which might increase the risk
of venous thromboembolism.
Introduction
Each year, over 25 000 people in England die from venous
thromboembolism developed in hospital.
1 This number is more
than the combined total of deaths from breast cancer, AIDS,
and traffic accidents, and more than 25 times the number of
deathsfrommeticillinresistantStaphylococcusaureus.
1Venous
thromboembolism is an important and preventable cause of
morbidity and mortality,
2 with almost a third of survivors
experiencing long term effects.
3 4 To improve survival and to
prevent complications, the occurrence of venous
thromboembolism needs to be reduced.
5
Independent risk factors for venous thromboembolism have
been identified
6-8 and prophylaxis exists for high risk
individuals.
9 In 2010, the UK National Institute for Health and
Clinical Excellence (NICE) issued new guidance to improve
the prevention of venous thromboembolism for patients by use
of cost effective interventions.
10 The guidance highlighted the
need for new research to develop and validate risk prediction
models to predict absolute risk of venous thromboembolism,
taking account of patient factors, comorbidity, and concurrent
medication,andincorporatingvenousthromboembolismevents
arising in a community setting.
10 It recommended the
development of new risk prediction models by use of primary
care research databases.
10 Such databases, with linked cause of
death data, contain robust information on many of the relevant
exposures and outcomes.
11 They are also represent the
populations where such a model is likely to be used to inform
treatment decisions, including the use of prophylaxis
10 and the
use of medication which might increase venous
thromboembolism risk.
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Research
RESEARCHOnce validated, suitable clinical risk prediction models can be
integratedintoclinicalcomputersystemstohelpsystematically
identify individuals at high risk of venous thromboembolism
and to alert clinicians to those who might benefit from
interventions.
12 13 Although there are currently no validated
algorithmstopredictriskforvenousthromboembolismdesigned
for use in primary care, computerised clinical decision support
could improve appropriate use of thromboprophylaxis in a
hospital setting.
14
We developed and validated a risk prediction algorithm
(QThrombosis)toestimatetheindividualabsoluteriskofvenous
thromboembolismtotargetprophylaxistothepeoplemostlikely
to benefit.
10 15 The algorithm could also be used to inform
treatment decisions regarding use of medication that may
increaseriskofvenousthromboembolism,suchasthecombined
oral contraceptive pill,
7 8 16-18 11 hormone replacement
therapy,
7 8 19-21andantipsychoticmedication.
8Wedevelopedthe
algorithm to estimate the risk of individuals developing venous
thromboembolism up to five years into the future, rather than
the current risk of having venous thromboembolism in patients
presenting with symptoms such as swollen legs.
Methods
Study design and data source
We did a prospective open cohort study in a large population
of primary care patients using the QResearch database (version
29). We included all general practices in England and Wales
thathadbeenusingtheircomputersystemswithEgtonMedical
Information Systems (EMIS) for at least a year. We randomly
allocated two thirds of practices to a derivation dataset and the
remainingthirdtoavalidationdatasetusingtherandomnumber
utility in Stata.
Weidentifiedanopencohortofpatientsaged25-84yearsdrawn
from patients registered with general practices between 1
January2004and30April2010.Weexcludedpatientswhodid
not have a postcode related Townsend score, patients with a
history of venous thromboembolism, and those who had been
prescribed oral anticoagulation drugs at any time before the
study start date. We also excluded women with recorded
evidence of pregnancy in the preceding 12 months, because the
risk of venous thromboembolism in pregnancy is likely to
requireseparateanalysisusingdatawheregestation,mode,and
dateofdeliverydatesarewellrecorded.Entrytothecohortwas
the latest of two dates: the study start date (1 January 2004) or
12 months after the patient registered with the practice. We
censored patients at the earliest date of a diagnosis of venous
thromboembolism, death, deregistration with the practice, last
upload of computerised data, five years after study entry, or the
study end date (30 April 2010).
Clinical outcomes
Our clinical outcome was incident diagnosis of venous
thromboembolism including either deep vein thrombosis or
pulmonary embolism, recorded either on the patients’ general
practice record using the relevant Read diagnostic codes or on
their linked Office of National Statistics cause of death record
using the relevant International Classification of Diseases
(ICD)-9 codes or ICD-10 diagnostic codes. We used codes
similar to those used in previous studies where possible.
16
Risk factors
We examined predictor variables based on established risk
factors for venous thromboembolism, focusing on those that
are likely to be recorded in the patient’s electronic record and
that the patient is likely to know (box 1).
We defined recent events as events recorded in the 12 months
before study entry, and we categorised them as: within the past
6 months, 6-12 months ago, or not in the past 12 months. We
defined current medication use as at least one prescription in
the 30 days preceding study entry for antipsychotic drugs and
tamoxifen, since most prescriptions are issued monthly. We
defined current use of oral contraceptives and hormone
replacement therapy as at least one prescription in the past six
months, since most prescriptions are issued for this period.
Derivation and validation of the models
Wedevelopedandvalidatedtheriskpredictionalgorithmusing
established methods.
10 12 30-33 We used multiple imputation to
replacemissingvaluesforbodymassindexandsmokingstatus,
and used these values in our main analyses.
34-37 We carried out
five imputations. We used Cox proportional hazards models to
estimate the coefficients for risk factors for men and women
separately, using robust variance estimates to allow for the
clusteringofpatientswithingeneralpractices.WeusedRubin’s
rules to combine the results across the imputed datasets.
38 We
used fractional polynomials to model non-linear risk relations
with continuous variables.
39 We fitted a full model initially and
retained variables if they had a hazard ratio of more than 0.80
or less than 1.20 (for binary variables) and were significant at
the 0.01 level. To simplify the model, we then focused on
variables for the most common conditions and medications and
combinedsimilarvariableswithcomparablehazardratioswhere
possible. We compared Akaike information criteria for models
with and without Townsend score to determine the score’s
contribution.
Weexaminedinteractionsbetweenpredictorvariablesandage.
We used the regression coefficients for each variable from the
final model as weights, which we combined with the baseline
survivor function evaluated for each year up to five years to
derive risk equations at each year of follow up.
40 We estimated
the baseline survivor function based on zero values of centred
continuousvariables,withallbinarypredictorvaluessettozero,
using the methods implemented in Stata.
We used multiple imputation in the validation cohort to replace
missing values for body mass index and smoking. We then
applied the risk equations for men and women obtained from
the derivation cohort to the validation cohort and calculated
measures of discrimination. We calculated the R
2 statistic
41
(estimated variation in time to venous thromboembolism), the
D statistic
42 (a measure of discrimination where higher values
indicate better discrimination), and the area under the receiver
operatingcharacteristiccurve(receiveroperatingcurvestatistic)
at one and five years. We assessed calibration (comparing the
mean predicted risks at one and five years with the observed
risk by tenth of predicted risk. We obtained the observed risk
by using the Kaplan-Meier estimate evaluated at one and five
years.
We applied the algorithm to the validation cohort to define the
thresholdsforthe0.5%,1%,5%,and10%ofpatientsathighest
estimatedriskofvenousthromboembolismatoneandfiveyears.
We used all the available data on the database to maximise the
powerandgeneralisabilityoftheresults.WeusedStata(version
11) for all analyses.
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RESEARCHBox 1 Predictor variables based on established risk factors for venous thromboembolism
• Age
7 8 (continuous)
• Body mass index
7 8 11 22 (continuous)
• Smoking status
7 8 22 11 (non-smoker; ex-smoker; light, moderate, or heavy smoker)
• Townsend deprivation score
7 8 (continuous)
• Varicose veins
6 8 (yes/no)
• Congestive cardiac failure
8 23 24 25 (yes/no)
• Rheumatoid arthritis
7 24 (yes/no)
• Chronic renal disease
7 8 (yes/no)
• Inflammatory bowel disease
8 24 26 27 (yes/no)
• Cancer
6-8 23 28 (lung, gastrointestinal, pancreas, renal, breast, prostate, other)
• Recent hospital admission
6 8 (yes/no)
• Recent hip fracture or hip surgery (or both)
8 (yes/no)
• Current use of antipsychotic drugs
7 8 (none, atypical, typical)
• Current use of tamoxifen
8 28 (yes/no)
• Current use of hormone replacement therapy
7 8 19-21 (none, equine or non-equine hormone replacement therapy)
• Use of antiplatelets (yes/no)
• Cardiovascular disease
6-8 (stroke, transient ischaemic attack, or coronary heart disease)
• Atrial fibrillation (yes/no)
• Asthma
7 8 (yes/no)
• Chronic obstructive pulmonary disease
7 8 (yes/no)
• Family history of venous thromboembolism
29 (yes/no)
Results
Overall study population
Overall, 564 QResearch practices in England and Wales met
our inclusion criteria, of which 375 were randomly assigned to
thederivationdatasetwiththeremainderassignedtoavalidation
cohort. We identified 2 598 829 patients aged 25-84 years in
the derivation cohort. We excluded 152 719 (5.9%) patients
without a recorded Townsend score, 26 211 (1.0%) on oral
anticoagulation treatment, 85 306 (3.3%) with evidence of
pregnancy in the preceding 12 months, 168 (0.01%) with a
missing date for venous thromboembolism, and 19 724 (0.8%)
with a history of venous thromboembolism. These exclusions
left 2 314 701 patients for analysis.
We identified 1 354 517 patients aged 25-84 years in the
validation cohort. We excluded 44 973 (3.3%) patients without
a recorded Townsend score, 13 815 (1.0%) on oral
anticoagulation, 44 318 (3.3%) with evidence of pregnancy in
the preceding 12 months, 113 with a missing date for venous
thromboembolism, and 10 696 (0.6%) with a history of venous
thromboembolism. These exclusions left 1 240 602 patients for
analysis.
The baseline characteristics of each cohort were similar (table
1). As in previous studies,
12 13 30 the patterns of missing data
supported the use of multiple imputation to replace missing
values for smoking and body mass index (not shown, available
from the authors).
Rates of incident venous thromboembolism
In the derivation cohort, we identified 14 756 incident cases of
venousthromboembolismarisingfrom10095199personyears
of observation, giving a rate of 14.6 per 10 000 person years.
Ofthese14756cases,5799(39.3%)werepulmonaryembolism
and8957(60.7%)weredeepveinthrombosis.Weidentified14
039 (95.1%) cases of venous thromboembolism from general
practice records and 717 (4.9%) solely from linked Office of
National Statistics death records.
In the validation cohort, we identified 6913 incident cases of
venous thromboembolism arising from 4 632 694 person years
of observation, giving a rate of 14.9 per 10 000 person years.
Of these 6913 cases, we identified 6526 (94.4%) from general
practice records and 387 (5.6%) solely from linked Office of
National Statistics death records.
Predictor variables
After fitting a full model, we combined variables that were
similar with comparable hazard ratios where possible. For
example, we combined the various types of cancer into one
variable (any cancer) since the hazard ratios for the individual
types of cancer were similar and the 95% confidence intervals
overlapped. Similarly, we combined the variables for current
useoftypicalandatypicalantipsychoticdrugsintoonevariable
and equine and non-equine hormone replacement therapy into
another variable. For example, the adjusted hazard ratio for
women was 1.27 (95% confidence interval 1.16 to 1.40) for
typical antipsychotic drugs and 1.69 (1.36 to 2.11) for atypical
antipsychotic drugs. The adjusted hazard ratio for both types of
antipsychotic drugs combined was 1.55 (1.32 to 1.81). We also
combined two variables for hip fracture or operation and recent
hospital admission.
Table 2 shows the predictor variables selected for the final
simplifiedmodelsformenandwomen.Wefoundnosignificant
interaction terms with age.
The risk of venous thromboembolism in women was linked to
increasing age, body mass index, and quantity of cigarettes
smoked every day. Risks were also raised in women with
varicoseveins(40%increase),congestivecardiacfailure(40%),
chronic renal disease (60%), any cancer (85%), chronic
obstructiveairwaysdisease(41%),inflammatoryboweldisease
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RESEARCH(45%), and those admitted to hospital in the past six months
(86%).
The risk of venous thromboembolism increased in women
prescribed antipsychotic drugs, (55% increase), oral
contraceptives(33%),hormonereplacementtherapy(20%),and
tamoxifen(48%).Althoughtheriskofvenousthromboembolism
rose with increasing levels of deprivation, the effect was not
markedanddidnotsubstantiallyaffectthemodelfit.Therefore,
we did not include deprivation in the final model.
Our final model for men included similar variables except for
those variables specific to women (hormone replacement
therapy, oral contraceptives, and tamoxifen). The magnitudes
of the adjusted hazard ratios were generally similar to those
found for women.
In our multivariate analysis, we found no significant change in
risk in men or women for: current antiplatelet therapy, atrial
fibrillation, cardiovascular disease, asthma, or family history
of venous thromboembolism (although the number of patients
with family history of venous thromboembolism recorded was
very low).
Validation
Discrimination
Thevalidationstatistics(table3)showedthattheriskprediction
algorithm explained 33% of the variation in time to venous
thromboembolismforwomenand34%formeninthevalidation
cohort when evaluated over five years. At five years, the D
statistic was 1.43 for women and 1.45 for men. The receiver
operating curve statistic was 0.75 in both sexes. The
performance of the algorithm over five years was marginally
better than the performance over one year (table 3).
Calibration
Thefigurecomparesthemeanpredictedriskswiththeobserved
risks at one and five years, by tenths of the distribution of
predicted risk, to assess the calibration of the model in the
validationcohort.Wefoundaclosesimilaritybetweenthemean
predicted risks and the observed risks at one and five years
withineverytenthofpredictedrisk,indicatingthatthealgorithm
was well calibrated. For example, in the top tenth of predicted
risk for women, the mean predicted five year risk was 2.78%
and the observed risk was 2.70%, giving a ratio of 1.03. For
men, the corresponding figures were 2.46% and 2.35% , giving
a ratio of 1.05.
Thresholds and risk stratification
Since the QThrombosis algorithm is new (box 2), we had no
establishedthresholdsfordefiningahighriskgroup.Therefore,
wecalculatedcut-offstodefinethetop0.5%,1%,5%,and10%
for absolute risk of venous thromboembolism based on the
estimated risks at one and five years in the validation cohort
(men and women combined).
Table4showsthecut-offs,andthetotalnumberofpatientsthat
would fall into each group based on the one and five year risk.
It also shows the total number of incident cases of venous
thromboembolism occurring in the groups and the overall total
numberofcasesofvenousthromboembolism.Forexample,the
90thcentiledefinedahighriskgroupwithafiveyearriskscore
ofmorethan15per1000.Therewere2441newcasesofvenous
thromboembolism within this group over five years, which
accountedfor35%ofallnewcasesofvenousthromboembolism.
In other words, the sensitivity was 35% for this cut-off. The
positivepredictivevalueatthiscut-offwas2%.The99thcentile
defined a high risk group with a five year risk score of more
than 38 per 1000. There were 350 new cases of venous
thromboembolism in this group over five years. The sensitivity
based on the 99th centile was 5% and the positive predictive
value was 2.8%.
Clinical example 1
A 39 year old woman, who is a heavy smoker, has a body mass
index of 36.7 and a history of varicose veins, and is currently
takingtheoralcontraceptivepill.Shehasaoneyearthrombosis
risk of 0.2% and a five year risk of 1.1%. A similar woman not
currently prescribed the oral contraceptive pill has a one year
risk of 0.15% and a five year risk of 0.9%.
Clinical example 2
A 54 year old woman, who is a moderate smoker, has a body
mass index of 36.7, a history of varicose veins, and chronic
obstructive airways disease. She has been admitted to hospital
in the past six months, and is currently prescribed hormone
replacementtherapy.Shehasaoneyearthrombosisriskof0.8%
and a five year risk of 4.5%. A similar woman not currently
prescribed hormone replacement therapy has a one year risk of
0.7% and a five year risk of 3.8%.
Clinical example 3
A 78 year old man, who is a heavy smoker, has a body mass
indexof29.4,chronicobstructiveairwaysdisease,chronicrenal
disease, and congestive cardiac failure, and is currently
prescribed an antipsychotic drug. He has a one year thrombosis
risk of 4.2% and a five year risk of 20.7%. A similar man not
currently prescribed antipsychotic drugs has a one year risk of
2.3% and a five year risk of 11.8%.
Clinical example 4
An 80 year old woman, who is an ex-smoker, has a body mass
index of 27.6, congestive cardiac failure, chronic renal disease,
and breast cancer. She has been admitted to hospital in the past
six months and is currently prescribed tamoxifen and an
antipsychotic drug. She has a one year thrombosis risk of 7.1%
and a five year risk of 33.5%. A similar woman not prescribed
tamoxifen or antipsychotic drugs has a one year risk of 3.2%
and a five year risk of 16.4%.
Discussion
Venousthromboembolismisacommon,lethalconditionwhich
can be prevented with the appropriate use of effective
interventionsinhighriskindividuals.
10Wehavedevelopedand
validated a new risk prediction algorithm designed to predict
the absolute risk of venous thromboembolism in a large
representative primary care population. This algorithm could
be used to identify patients at highest risk of venous
thromboembolism and those most likely to benefit from
intervention, such as change in medication, mechanical
prophylaxis,orthromboprophylacticmedication.Thealgorithm
is not, however, designed to assess the current risk of venous
thromboembolism—for example, in a symptomatic patient
presentingwithaswollenleg.Wethinkourstudyprovidesnew
information which helps address gaps in evidence highlighted
by recent NICE guidance.
10
Althoughourstudyhasfocusedontheformaldevelopmentand
validationofthealgorithm,wecanseeseveralclinicalsituations
wherethealgorithmembeddedinaclinicalriskcalculatormight
be useful. Firstly, it could be used to identify patients at
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RESEARCHBox 2 QThrombosis web calculator
A simple web calculator implements the QThrombosis algorithm and is publicly available. It also has the open source
software for download (www.qthrombosis.org)
increasedriskofvenousthromboembolismonorbeforehospital
admission or before long haul flights, so that prophylaxis can
be considered in a more systematic way.
10
Secondly, the algorithm could be used when considering
medication which might increase venous thromboembolism
risk, such as the oral contraceptive pill, tamoxifen, hormone
replacement therapy, or antipsychotic drugs. For example, a
woman might be interested to know her absolute level of risk
and how it might change with medication, and this risk can be
assessed against the expected benefits of the medication.
Thirdly,thealgorithmcouldbeusedtoidentifyhighriskgroups
of patients suitable for further testing, closer monitoring, or
preventativetreatment.Pragmaticrandomisedtrialscanestablish
the true benefits of preventive treatment in individuals at high
risk of thromboembolic events and the exact cut-offs for
treatment where the benefits will outweigh the risks. We have
presented clinical examples of estimated absolute risk at one
and five years although the algorithm can calculate risks at 1,
2, 3, 4, or 5 years; therefore, relevant risks can be calculated
depending on the clinical situation and intervention being
considered.
Other studies of risk models
While other studies have examined risk factors for venous
thromboembolism,studiesspecificallydesignedtodevelopand
validateriskpredictionalgorithmsforvenousthromboembolism
are lacking. We identified only one cohort study which
developedariskpredictionscoreforvenousthromboembolism
over a 10 year observation period starting in 1993. Heinemann
andcolleaguesreportedtheBavarianthromboembolicriskwhich
examinedvenousthromboembolismriskin4337youngwomen
(18-55 years) using genetic information and self reported
outcomes via a questionnaire followed up by a telephone
interview.
43 The sample was limited by size since it included
only 34 cases of venous thromboembolism. However, it was
the first such study and included a careful analysis of many
candidate variables including age, body mass index, varicose
veins, use of hormone replacement therapy, family history of
cardiovascular disease, oral contraceptive use, smoking status,
educational attainment, reproductive history, and laboratory
measurements, but no acute events such as surgery or
immobilisation.Mostofthesevariableswerenot,importantand
did not improve prediction, or were considered impractical to
use.Hence,theirfinalmodelincludedonlythreevariables(age,
body mass index, and family history) in addition to genetic
information.WhiletheBavarianthromboembolicriskalgorithm
was not published or validated, their analysis and commentary
did support the use of such an algorithm for future risk
stratification.Thestudyalsoconcludedthatthealgorithmcould
be based on clinical data alone at least until better genetic
information is more available.
43
More recently, a predictive model for chemotherapy associated
thrombosis has been developed in 2701 patients with selected
cancersundergoingchemotherapyinahospitaloutpatientsetting
followed up over a median of 2.5 months.
44 The algorithm was
based on five predictive variables: site of cancer, body mass
index, use of erythropoiesis stimulating agent, haemoglobin
more than 100g/L, and leucocyte count of more than 11×10
9/L.
The same team validated the predictive model in 1365 patients
from the same study
44 with a C statistic of 0.7 (which is lower
thanthereceiveroperativecurvevalueof0.75fromourpresent
study). Our study is more suitable for use in a general primary
care population.
Strengths
The strengths and weaknesses of general practice databases for
the development and validation of clinical risk prediction
algorithms have been described in detail elsewhere.
12 32 In
summary, key strengths include size; duration of follow-up;
representativeness;andlackofselection,recall,andrespondent
bias. UK general practices have good levels of accuracy and
completeness in recording clinical diagnoses and prescribed
medications,
45 46
We think our study has good face validity since it has been
undertaken in the setting where most patients in the UK are
assessed, treated, and followed up. Our study also includes
established exposures known to increase risk of venous
thromboembolism. We have been able to include a long list of
predictor variables and establish which factors remain
independentafteradjustmentandtheirrelativeimportance.The
strength of the association between cancer and risk of venous
thromboembolism is similar to that reported elsewhere.
28 The
size of our study is particularly important since venous
thromboembolism is uncommon in certain population groups.
We have also developed the algorithm in one cohort and
validateditinaseparatecohortthatrepresentsthepatientslikely
to be considered for preventative measures. Although the
validation cohort is derived from general practices using the
same clinical computer system (EMIS), they were physically
discrete. Also, since this computer system is used in over half
ofUKgeneralpractices,ourresultsarelikelytogeneralisewell.
A separate independent validation study using another general
practice database is planned (to be undertaken by another
independent team).
Limitations
Limitations included lack of formally adjudicated outcomes,
information bias, potential for missing data, and residual
confounding. Our database has linked cause of death from the
UK Office of National Statistics, and our study is therefore
likelytohavepickedupmostcasesofvenousthromboembolism
thereby minimising ascertainment bias. Patients who die from
venous thromboembolism in hospital will have the cause of
death recorded on their death certificate and therefore will be
included on the linked cause of death data. Other patients who
have been diagnosed with but do not die from venous
thromboembolisminhospitalwillhavetheinformationrecorded
in hospital discharge letters which are sent to the general
practitionerandthenenteredintothepatient’selectronicrecord.
The recorded clinical diagnoses of venous thromboembolism
were not independently verified for the study, but in other
studiestheinclusionofpossiblevenousthromboembolismcases
gave similar adjusted odds ratios to that based on confirmed
cases.
11Theobservedincidencerateinourpopulationwasclose
to the 11.7 per 10 000 person years reported elsewhere
47 and in
linewiththeestimated5-10per10000personyearsforwomen
of reproductive age.
48 Although we are reliant on the accuracy
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RESEARCHof information recorded by primary care physicians, we think
thatthequalityofinformationislikelytobegoodsinceprevious
studies have validated similar outcomes and exposures using
questionnaire data and found levels of completeness and
accuracy to be high.
11
Although genes associated with increased risk of venous
thromboembolism have been identified,
49 such information is
not routinely collected or recorded in electronic records and
hence we were unable to include genetic information in our
analysis. We concluded that although the absence of genetic
information may be a limitation of our study, it is unlikely to
have a major effect on the use of the QThrombosis algorithm,
because such information is unlikely to be available for use in
a general risk calculator.
Wedesignedthisstudytoidentifypatientsathighriskofvenous
thromboembolism who might require prophylaxis before a
hospital procedure or other event rather than to help diagnose
itinsymptomaticpatients.Similarly,ourstudywasnotdesigned
to estimate how the risk of thromboembolism might change
during the course of a hospital episode. Further analysis of this
kind might be possible once the QResearch database is linked
to secondary care data.
Furthermore,ourfindingscannotofferhypothesesonindividual
mechanisms in the genesis of thromboembolism for comorbid
conditions or individual drugs. For some clinical conditions
(such as cancer), biological mechanisms have already been
proposed.
50Eveninadatasetofthissize,thenumberofpatients
exposed to some individual drugs is too small to estimate
separate hazard ratios. We cannot rule out the possibility of
residual confounding by indication, which is a further barrier
tomakingdefinitiveriskcomparisonsbetweenindividualdrugs.
However, in terms of our overall findings, the direction and the
magnitude of the hazard ratios associated with risk of venous
thromboembolism are broadly in line with those reported
elsewhere,
29withlargesteffectsseeninassociationwithcancer,
28
recenthipfracture,hipsurgery,andhospitaladmission.
15Family
history was not associated with risk of venous
thromboembolism, yet this finding is likely to reflect the small
numbers of patients with this information recorded.
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RESEARCHTables
Table 1| Baseline characteristics of patients in derivation and validation cohorts
Validation cohort
(n=1 240 602)
Derivation cohort
(n=2 314 701)
637 482 (51.4) 1 190 500 (51.4) Male
603 120 (48.6) 1 124 201 (48.6) Female
47.7 (15.7) 47.6 (15.7) Mean age (SD)
−0.1 (3.5) −0.1 (3.5) Mean Townsend score (SD)
975 051 (78.6) 1 828 253 (79.0) BMI recorded
26.4 (4.8) 26.4 (4.8) Mean BMI (SD)
1 160 241 (93.5) 2 168 137 (93.7) Smoking status recorded
970 083 (78.2) 1 818 859 (78.6) BMI and smoking status recorded
Smoking status
634 966 (51.2) 1 187 610 (51.3) Non-smoker
231 139 (18.6) 430 425 (18.6) Ex-smoker
42 591 (3.4) 64 622 (2.8) Smoking amount not recorded
82 943 (6.7) 168 021 (7.3) Light smoker (<10 cigarettes/day)
98 492 (7.9) 189 805 (8.2) Moderate smoker (10-19 cigarettes/day)
70 110 (5.7) 127 654 (5.5) Heavy smoker (≥20 cigarettes/day)
Medical and family history
27 (0.0) 67 (0.0) Family history of venous thromboembolism
21 737 (1.8) 41 054 (1.8) Varicose veins
7910 (0.6) 15 081 (0.7) Congestive cardiac failure
8918 (0.7) 16 601 (0.7) Rheumatoid arthritis
3275 (0.3) 5957 (0.3) Chronic renal disease
7761 (0.6) 14 910 (0.6) Inflammatory bowel disease
723 (0.1) 1526 (0.1) Lung cancer
3981 (0.3) 7633 (0.3) Gastrointestinal cancer
104 (0.0) 197 (0.0) Pancreatic cancer
1685 (0.1) 3209 (0.1) Renal cancer
7399 (0.6) 14 004 (0.6) Breast cancer (women only)
3326 (0.3) 6326 (0.3) Prostate cancer (men only)
9582 (0.8) 18 316 (0.8) Other cancers
28 471 (2.3) 51 343 (2.2) Current typical antipsychotic drugs
6841 (0.6) 13 031 (0.6) Current atypical antipsychotic drugs
53 654 (4.3) 98 690 (4.3) Current oral contraceptives (women only)
28 291 (2.3) 52 218 (2.3) Current hormone replacement therapy (women only)
3849 (0.3) 7116 (0.3) Current tamoxifen (women only)
1318 (0.1) 2777 (0.1) Hip fracture or replacement in past 182 days
16 106 (1.3) 27 657 (1.2) Hospital admission in past 182 days
BMI=body mass index. Figures in the tables are number (%) unless otherwise specified.
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RESEARCHTable 2| Adjusted hazard ratios (95% CI) for final models in derivation cohort
Men Women
P value
Adjusted hazard ratio*
(95% CI) Events (No) P value
Adjusted hazard ratio*
(95% CI) Events (No)
Smoking status
– 1.00 3148 – 1.00 4533 Non-smoker
0.070 1.06 (0.995 to 1.13) 2238 0.030 1.07 (1.01 to 1.15) 1689 Ex-smoker
<0.001 1.22 (1.09 to 1.35) 618 0.001 1.22 (1.09 to 1.37) 443 Light smoker
<0.001 1.37 (1.22 to 1.52) 592 0.003 1.17 (1.05 to 1.29) 558 Moderate smoker
<0.001 1.49 (1.33 to 1.66) 562 <0.001 1.34 (1.18 to 1.52) 375 Heavy smoker
Medical history
<0.001 1.38 (1.18 to 1.63) 172 <0.001 1.40 (1.24 to 1.58) 407 Varicose veins
0.001 1.33 (1.13 to 1.57) 168 <0.001 1.40 (1.2 to 1.62) 206 Congestive cardiac failure
<0.001 1.92 (1.50 to 2.44) 62 0.003 1.60 (1.17 to 2.19) 46 Chronic renal disease
<0.001 2.18 (1.97 to 2.41) 505 <0.001 1.85 (1.69 to 2.03) 573 Any cancer
<0.001 1.62 (1.45 to 1.80) 429 <0.001 1.41 (1.24 to 1.62) 360 Chronic obstructive airways
disease
0.001 1.5 (1.18 to 1.91) 94 0.002 1.45 (1.15 to 1.82) 87 Inflammatory bowel disease
<0.001 1.93 (1.64 to 2.27) 209 <0.001 1.86 (1.63 to 2.14) 244 Hospital admission in past
six months
Current medication
<0.001 1.84 (1.51 to 2.23) 121 <0.001 1.55 (1.32 to 1.81) 187 Antipsychotic drugs†
NA NA NA <0.001 1.48 (1.19 to 1.84) 97 Tamoxifen†
NA NA NA 0.001 1.33 (1.12 to 1.58) 229 Oral contraceptives†
NA NA NA 0.001 1.20 (1.08 to 1.34) 447 Hormone replacement
therapy†
95% CI=95% confidence intervals. NA=not applicable. *Hazard ratios adjusted for all other terms in the table, age, and body mass index (BMI). Models included
fractional polynomial terms for age and BMI. For women, terms were age
−0.5, ln(age), BMI
−2, BMI
−2ln(BMI). For men, terms were age
3, age
3ln(age), BMI
−2, BMI
−2ln(BMI).
†Compared with patients without this characteristic.
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RESEARCHTable 3| Validation statistics for risk prediction algorithm in validation cohort
Mean (95% CI) evaluated at five years Mean (95% CI) evaluated at one year
Women
32.78 (31.08 to 34.48) 28.02 (24.60 to 31.44) R
2 statistic (%)*
1.43 (1.37 to 1.49) 1.28 (1.17 to 1.39) D statistic†
0.75 (0.74 to 0.76) 0.71 (0.70 to 0.73) ROC statistic†
Men
33.51 (31.71 to 35.30) 31.11 (27.57 to 34.64) R
2 statistic (%)
1.45 (1.39 to 1.51) 1.38 (1.26 to 1.49) D statistic
0.75 (0.74 to 0.76) 0.72 (0.70 to 0.74) ROC statistic
*Statistic shows explained variation (higher values indicate that more variation is explained). †ROC=receiver operating curve. ROC statistic is a measure of
discrimination (higher values indicate better discrimination).
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RESEARCHTable 4| Incident cases of venous thromboembolism in groups of predicted risk within one and five years, in validation cohort (men and
women combined)
Positive predictive
value (%) Sensitivity (%)
Total no of new VTE
diagnoses
No of patients in risk
group with new VTE
diagnosis
No of patients in risk
group
Riskthresholdper
1000
Five year risk
2.0 35.3 6913 2441 124 060 15 Top 10% risk score
2.3 20.3 6913 1400 62 027 21 Top 5% risk score
2.8 5.1 6913 350 12 405 38 Top 1% risk score
3.1 2.8 6913 191 6203 48 Top 0.5% risk score
One year risk
0.5 35.3 1686 595 124 042 3 Top 10% risk score
0.6 21.1 1686 356 62 018 4 Top 5% risk score
0.8 6.0 1686 101 12 406 7 Top 1% risk score
0.9 3.4 1686 57 6202 9 Top 0.5% risk score
VTE=venous thromboembolism.
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RESEARCHFigure
Mean predicted risks and observed risks of venous thromboembolism by tenth of predicted risk, applying risk prediction
scores to the validation cohort
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